Alfasigma to participate at United European Gastroenterology Week -12-15 October

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced its participation in the United European Gastroenterology (UEG) Week 2024. Taking place from 12-15 October in Vienna, the international conference is one of the most important annual conferences in this therapeutic area.

During the conference, several Alfasigma driven presentations and abstracts focused on ulcerative colitis and chronic intestinal pseudo-obstruction will be showcased and Alfasigma will be based at booth 26 in Hall B.

This is the first conference in which Alfasigma is participating since becoming the marketing authorisation holder for Jyseleca® in the European Union and Great Britain, announced in August and September respectively. The market authorization transfers followed the transaction completed on January 31, 2024, in which Alfasigma acquired the Jyseleca® (filgotinib) business from Galapagos NV.